Elicio Therapeutics, INC

Elicio Therapeutics announced the pricing of a registered direct offering expected to raise approximately $15 million in gross proceeds.

Elicio Therapeutics presented clinical data showing complete responses in metastatic pancreatic cancer patients treated with ELI-002 7P followed by checkpoint inhibition.

Elicio Therapeutics announced preliminary clinical observations from its Phase 2 AMPLIFY-7P study, showing complete responses in pancreatic cancer patients treated with ELI-002 7P and subsequent checkpoint inhibition.

Elicio Therapeutics announced Phase 2 AMPLIFY-7P study results for ELI-002 7P in adjuvant pancreatic cancer, which did not meet its primary endpoint in the overall population but showed promise in a specific subgroup.

Elicio Therapeutics announced first quarter 2026 financial results, highlighting progress in its Phase 2 AMPLIFY-7P trial for pancreatic cancer and an extended cash runway.

Elicio Therapeutics, Inc. has established a new at-the-market equity offering program for up to $100 million, replacing a previous $40 million agreement.

Elicio Therapeutics reports a decrease in R&D expenses for Q1 2026, alongside an increase in G&A costs, and highlights ongoing concerns about its ability to continue as a going concern.

Elicio Therapeutics reports reduced net losses in Q3 2025 but faces substantial doubt about its ability to continue as a going concern due to dwindling cash reserves.

Elicio Therapeutics reported increased net losses and a going concern warning, despite recent capital raises and positive clinical trial safety data for ELI-002 7P.

Elicio Therapeutics reports a net loss of $11.2 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern.

Elicio Therapeutics reports a net loss of $18.8 million for the third quarter of 2024, alongside updates on clinical trials and financial activities.

Elicio Therapeutics, a clinical-stage biotechnology company, announced its second quarter 2024 financial results, highlighting ongoing clinical development and financial challenges.

Elicio Therapeutics details its financial performance for 2024 and highlights the expected Q3 2025 interim analysis of its Phase 2 AMPLIFY-7P trial.

Elicio Therapeutics has filed an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and updated certifications from its principal executive and financial officers.

Elicio Therapeutics has amended its non-employee director compensation policy, outlining cash retainers, committee chair and member fees, and equity awards for board service.

Christopher Haqq, See Remarks of Elicio Therapeutics, Inc., received 64,643 shares of common stock on July 16, 2026.

Peter Demuth, Chief Scientific Officer of Elicio Therapeutics, Inc., received 52,832 shares of common stock on July 16, 2026.

Preetam Shah, See Remarks of Elicio Therapeutics, Inc., received 60,833 shares of common stock on July 16, 2026.

Robert Connelly, CEO, President and Director and a Director of Elicio Therapeutics, Inc., received 186,944 shares of common stock on July 16, 2026.

Elicio Therapeutics CEO Robert Connelly received substantial equity awards, including restricted stock units and stock options, effective February 2, 2026.

Elicio Therapeutics, Inc. granted 24,000 restricted stock units and 47,900 stock options to Chief Strategy and Financial Officer Preetam Shah.

Elicio Therapeutics announces its annual stockholders meeting to be held virtually on May 19, 2025, featuring the election of directors and ratification of the company's independent accounting firm.

Elicio Therapeutics is holding its Annual Meeting of Stockholders on November 7, 2024, to elect directors, ratify the selection of its accounting firm, and approve the issuance of shares related to warrants and a convertible note.

GKCC, LLC and its manager Yekaterina Chudnovsky have increased their beneficial ownership in Elicio Therapeutics, Inc. to 48% through the issuance of new warrants and a $10 million senior secured promissory note.

Elicio Therapeutics, Inc. announced that GKCC, LLC, an entity controlled by board member Yekaterina Chudnovsky, converted a $20.3 million convertible note into 3,500,573 shares, increasing their beneficial ownership to 48.1% of the company's common stock.

Moti Investments LLC has reported beneficial ownership of 1,408,892 shares, representing 6.1% of the outstanding common stock of Elicio Therapeutics, Inc.

Knoll Capital Management, LLC, along with Fred Knoll and Gakasa Holdings, LLC, has reported beneficial ownership of 1,211,957 shares, representing 5.3% of Elicio Therapeutics, Inc.'s common stock.

Actyus Private Equity SGIIC, S.A. has filed an amended Schedule 13G, disclosing a 1.64% beneficial ownership stake in Elicio Therapeutics, Inc.

Actyus Private Equity SGIIC, S.A. has filed an amended Schedule 13G, reporting a 5.35% beneficial ownership stake in Elicio Therapeutics, Inc. as of March 31, 2025.

Knoll Capital Management, Fred Knoll, and Gakasa Holdings, LLC have jointly disclosed a beneficial ownership of 5.2% in Elicio Therapeutics, Inc.'s common stock.

Actyus Private Equity SGIIC, S.A. has reported a 5.45% beneficial ownership stake in Elicio Therapeutics, Inc., holding 587,818 shares of common stock.